Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 256

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial

Open access
Fennell, Dean A, Ewings, Sean, Ottensmeier, Christian, Califano, Raffaele, Hanna, Gerard G, Hill, Kayleigh, Danson, Sarah, Steele, Nicola, Nye, Mavis, Johnson, Lucy, Lord, Joanne, Middleton, Calley, Szlosarek, Peter, Chan, Sam, Gaba, Aarti, Darlison, Liz, Wells-Jordan, Peter, Richards, Cathy, Poile, Charlotte, Lester, Jason F, Griffiths, Gareth, Price, Gillian, Shaw, Paul, Cave, Judith, Naik, Jay, Ford, Amy, Geldhart, Tom, Dancey, Gairin, Papadatos, Dionysis, Polychronis, Andy, Jankowska, Petra, Scott, Angela, Gardiner, Jill, Cominos, Mathilda, Campbell, Lynn, MacGregor, Carol, Mullholand, Lois, Chitnis, Meenali, Dougherty, Gary · 2021 · The Lancet Oncology

Abstract

BACKGROUND: No phase 3 trial has yet shown improved survival for patients with pleural or peritoneal malignant mesothelioma who have progressed following platinum-based chemotherapy. The aim of this study was to assess the efficacy and safety of nivolumab, an anti-PD-1 antibody, in these patients. METHODS: This was a multicentre, placebo-controlled, double-blind, parallel group, randomised, phase 3 trial done in 24 hospitals in the UK. Adult patients (aged ≥18 years) with an Eastern Cooperative Oncology Group performance status of 0 or 1, with histologically confirmed pleural or peritoneal mesothelioma, who had received previous first-line platinum-based chemotherapy and had radiological evidence of disease progression, were randomly assigned (2:1) to receive nivolumab at a flat dose of 240 mg every 2 weeks over 30 min intravenously or placebo until disease progression or a maximum of 12 months. The randomisation sequence was generated within an interactive web response system (Alea); patients were stratified according to epithelioid versus non-epithelioid histology and were assigned in random block sizes of 3 and 6. Participants and treating clinicians were masked to group allocation. The co-primary endpoints were investigator-assessed progression-free survival and overall survival, analysed according to the treatment policy estimand (an equivalent of the intention-to-treat principle). All patients who were randomly assigned were included in the safety population, reported according to group allocation. This trial is registered with Clinicaltrials.gov, NCT03063450. FINDINGS: Between May 10, 2017, and March 30, 2020, 332 patients were recruited, of whom 221 (67%) were randomly assigned to the nivolumab group and 111 (33%) were assigned to the placebo group). Median follow-up was 11·6 months (IQR 7·2-16·8). Median progression-free survival was 3·0 months (95% CI 2·8-4·1) in the nivolumab group versus 1·8 months (1·4-2·6) in the placebo group (adjusted hazard ratio [HR] 0·67 [95% CI 0·53-0·85; p=0·0012). Median overall survival was 10·2 months (95% CI 8·5-12·1) in the nivolumab group versus 6·9 months (5·0-8·0) in the placebo group (adjusted HR 0·69 [95% CI 0·52-0·91]; p=0·0090). The most frequently reported grade 3 or worse treatment-related adverse events were diarrhoea (six [3%] of 221 in the nivolumab group vs two [2%] of 111 in the placebo group) and infusion-related reaction (six [3%] vs none). Serious adverse events occurred in 90 (41%) patients in the nivolumab group and 49 (44%) patients in the placebo group. There were no treatment-related deaths in either group. INTERPRETATION: Nivolumab represents a treatment that might be beneficial to patients with malignant mesothelioma who have progressed on first-line therapy. FUNDING: Stand up to Cancer-Cancer Research UK and Bristol Myers Squibb.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(21)00471-x

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Research works printed but not linked: 1

  1. Fennell, 2021, A randomized phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma, Proc Am Soc Clin Oncol, 39, 8507, 10.1200/JCO.2021.39.15_suppl.8507 · doi:10.1200/jco.2021.39.15_suppl.8507

Cited by

See all 256

Metadata

Authors
Fennell, D. A., Ewings, S., Ottensmeier, C., Califano, R., Hanna, G. G., Hill, K., Danson, S., Steele, N., Nye, M., Johnson, L., Lord, J., Middleton, C., Szlosarek, P., Chan, S., Gaba, A., Darlison, L., Wells-Jordan, P., Richards, C., Poile, C., Lester, J. F., Griffiths, G., Price, G., Shaw, P., Cave, J., Naik, J., Ford, A., Geldhart, T., Dancey, G., Papadatos, D., Polychronis, A., Jankowska, P., Scott, A., Gardiner, J., Cominos, M., Campbell, L., MacGregor, C., Mullholand, L., Chitnis, M., & Dougherty, G.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2021-11
Volume
22
Issue
11
Pages
1530-1540
ISSN
1470-2045 (ISSN-L)
OpenAlex
W3207665479
Cited by
256
References
21
FWCI
26.10
Type
journal article
Language
en
Update notices
erratum (2025-05-01)
Open access
hybrid
Licence
Funders
  • Cancer Research UK (C16728/A21400)
  • University of Southampton
  • Bristol-Myers Squibb (CA 209\u2013841)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. https://app.cochat.ai/papers/10.1016/s1470-2045(21)00471-x
The paper
Fennell, D. A., Ewings, S., Ottensmeier, C., Califano, R., Hanna, G. G., Hill, K., Danson, S., Steele, N., Nye, M., Johnson, L., Lord, J., Middleton, C., Szlosarek, P., Chan, S., Gaba, A., Darlison, L., Wells-Jordan, P., Richards, C., Poile, C., . . . Dougherty, G. (2021). Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(21)00471-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.